BR112012001931A2 - métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv - Google Patents
métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcvInfo
- Publication number
- BR112012001931A2 BR112012001931A2 BR112012001931A BR112012001931A BR112012001931A2 BR 112012001931 A2 BR112012001931 A2 BR 112012001931A2 BR 112012001931 A BR112012001931 A BR 112012001931A BR 112012001931 A BR112012001931 A BR 112012001931A BR 112012001931 A2 BR112012001931 A2 BR 112012001931A2
- Authority
- BR
- Brazil
- Prior art keywords
- diagnosing
- outcome
- methods
- infected patients
- hcv infected
- Prior art date
Links
- 208000005176 Hepatitis C Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH12012009 | 2009-07-31 | ||
| US28253810P | 2010-02-26 | 2010-02-26 | |
| PCT/IB2010/053139 WO2011013019A1 (en) | 2009-07-31 | 2010-07-09 | Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012001931A2 true BR112012001931A2 (pt) | 2017-07-18 |
Family
ID=42727569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012001931A BR112012001931A2 (pt) | 2009-07-31 | 2010-07-09 | métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110165124A1 (enExample) |
| EP (1) | EP2459210A1 (enExample) |
| JP (1) | JP2013500713A (enExample) |
| KR (1) | KR20120040725A (enExample) |
| CN (1) | CN102665753A (enExample) |
| AU (1) | AU2010277239A1 (enExample) |
| BR (1) | BR112012001931A2 (enExample) |
| CA (1) | CA2768772A1 (enExample) |
| MX (1) | MX2012001058A (enExample) |
| WO (1) | WO2011013019A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5656159B2 (ja) * | 2009-08-24 | 2015-01-21 | 独立行政法人理化学研究所 | インターフェロン療法の効果予測用マーカー |
| AU2010334918B2 (en) * | 2009-12-22 | 2015-04-02 | Janssen Sciences Ireland Uc | Predictive value of IL28b gene polymorphism combined with pretreatment serum IP-10 quantification for response to peginterferon and ribavirin is enhanced in comparison with any of these biomarkers alone |
| WO2012107584A1 (en) | 2011-02-11 | 2012-08-16 | Universite Pierre Et Marie Curie (Paris 6) | Methods for predicting outcome of a hepatitis virus infection |
| CA2831428A1 (en) * | 2011-03-31 | 2012-10-04 | Novartis Ag | Alisporivir to treat hepatitis c virus infection |
| EP2726632A1 (en) * | 2011-06-30 | 2014-05-07 | Centre Hospitaller Universitaire Vaudois (CHUV) | Polymorphisms associated with non-response to a hepatitis c treatment or susceptibility to non-spontaneous hepatitis c clearance |
| EP2739301B1 (en) | 2011-08-03 | 2016-01-20 | Cytheris | Hcv immunotherapy |
| JP2013074888A (ja) * | 2011-09-15 | 2013-04-25 | Arkray Inc | ＩＬ２８Ｂ（ｒｓ８０９９９１７）とＩＴＰＡ（ｒｓ１１２７３５４）の変異を検出する方法 |
| US20140271542A1 (en) * | 2011-10-05 | 2014-09-18 | The United States Of America As Represented By The Secretary, Department Of Health And Human Service | Genetic marker for predicting prognosis in patients infected with hepatitis c virus |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| AU2013201406B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| EP2583680A3 (en) | 2011-10-21 | 2013-06-12 | Abbvie Inc. | Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV |
| WO2013148272A1 (en) | 2012-03-28 | 2013-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A NOVEL INTERFERON-λ4 (IFNL4) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF |
| CN102816838A (zh) * | 2012-07-06 | 2012-12-12 | 吉林艾迪康医学检验所有限公司 | 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒 |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CN108220424A (zh) * | 2018-02-05 | 2018-06-29 | 广州和康医疗技术有限公司 | 一种检测il28基因位点的方法及试剂盒 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5001050A (en) | 1989-03-24 | 1991-03-19 | Consejo Superior Investigaciones Cientificas | PHφ29 DNA polymerase |
| US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US5888780A (en) | 1992-12-07 | 1999-03-30 | Third Wave Technologies, Inc. | Rapid detection and identification of nucleic acid variants |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
| US6068818A (en) | 1993-11-01 | 2000-05-30 | Nanogen, Inc. | Multicomponent devices for molecular biological analysis and diagnostics |
| ZA959469B (en) | 1994-11-15 | 1996-05-15 | South African Druggists Ltd | Pharmaceutical composition |
| WO1997001603A1 (en) | 1995-06-26 | 1997-01-16 | Henkel Corporation | Methods of preparing inorganic pigment dispersions |
| US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
| CA2335951C (en) | 1998-06-24 | 2013-07-30 | Mark S. Chee | Decoding of array sensors with microspheres |
| GB9817266D0 (en) | 1998-08-07 | 1998-10-07 | Imperial College | Method |
| US6429027B1 (en) | 1998-12-28 | 2002-08-06 | Illumina, Inc. | Composite arrays utilizing microspheres |
| JP2005204549A (ja) * | 2004-01-21 | 2005-08-04 | Hubit Genomix Inc | Ｃ型肝炎ウイルス感染者の経過に関する遺伝子およびその利用 |
| US20080299094A1 (en) * | 2004-07-01 | 2008-12-04 | Medical Research Fund Of Tel Aviv | Methods and Kits for Predicting Liver Fibrosis Progression Rate in Chronic Hepatitis C Patients |
| CN102307589A (zh) * | 2008-08-28 | 2012-01-04 | 沃泰克斯药物股份有限公司 | Hcv的基因型分析 |
| EP2432898B1 (en) * | 2009-05-21 | 2014-11-26 | Merck Sharp & Dohme Corp. | Genetic markers associated with interferon-alpha response |
-
2010
- 2010-07-09 JP JP2012522282A patent/JP2013500713A/ja active Pending
- 2010-07-09 BR BR112012001931A patent/BR112012001931A2/pt not_active IP Right Cessation
- 2010-07-09 EP EP10740746A patent/EP2459210A1/en not_active Withdrawn
- 2010-07-09 KR KR1020127005379A patent/KR20120040725A/ko not_active Withdrawn
- 2010-07-09 WO PCT/IB2010/053139 patent/WO2011013019A1/en not_active Ceased
- 2010-07-09 CA CA2768772A patent/CA2768772A1/en not_active Abandoned
- 2010-07-09 AU AU2010277239A patent/AU2010277239A1/en not_active Abandoned
- 2010-07-09 CN CN2010800436612A patent/CN102665753A/zh active Pending
- 2010-07-09 MX MX2012001058A patent/MX2012001058A/es not_active Application Discontinuation
- 2010-07-29 US US12/846,356 patent/US20110165124A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2768772A1 (en) | 2011-02-03 |
| AU2010277239A1 (en) | 2012-02-02 |
| MX2012001058A (es) | 2012-06-19 |
| JP2013500713A (ja) | 2013-01-10 |
| WO2011013019A1 (en) | 2011-02-03 |
| CN102665753A (zh) | 2012-09-12 |
| EP2459210A1 (en) | 2012-06-06 |
| US20110165124A1 (en) | 2011-07-07 |
| KR20120040725A (ko) | 2012-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012001931A2 (pt) | métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv | |
| BR112012000352A2 (pt) | tapete ou tapete em placas | |
| BRPI1015379A2 (pt) | sistemas de cálculo biométrico e métodos | |
| EP2320045A4 (en) | APPARATUS FOR TREATING EXHAUST GAS | |
| HUE049880T2 (hu) | Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére | |
| BR112012029417A2 (pt) | detecção de análise de ataques maliciosos | |
| BRPI0910608A2 (pt) | métodos e sistemas para avaliar resultados clínicos | |
| HUE051377T2 (hu) | Eljárás betegségek gyógyászati chaperonnal történõ kezelésére adott válasz elõrejelzésére | |
| BRPI0906858A2 (pt) | Métodos para detecção de assinaturas de doença ou condições em fluidos corporais | |
| IL216472A0 (en) | Benzoxazepines based p13k/mtor inhibitors against proliferative diseases | |
| DK2286156T3 (da) | Datacenter med gulvvarme | |
| BRPI0813212A2 (pt) | Métodos de tratamento de doenças e distúrbios mediados por serotonina | |
| IT1400425B1 (it) | Modified snrnas for use in therapy. | |
| BR112013014063A2 (pt) | inibidores macrocíclicos do vírus flaviviridae | |
| BRPI0910854A2 (pt) | métodos de tratamento | |
| PT3412687T (pt) | Métodos de tratamento de dlbcl | |
| BR112012005438A2 (pt) | inibidores de vírus flaviviridae | |
| IT1391555B1 (it) | Apparato trattamento extracorporeo sangue | |
| EP2486509A4 (en) | PLATFORM SECURITY | |
| BRPI1006988A2 (pt) | mecanismo antitrapaça baseado em entidade confiável | |
| ME02952B (me) | Wnt antagonisti i metode tretiranja | |
| PL2594588T3 (pl) | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii | |
| BRPI1015209A2 (pt) | placa de osteossíntese com recurso de microincisões | |
| BR112012003844A2 (pt) | vacinas de pttv e diagnóstico | |
| EP2402875A4 (en) | Noise analysis design method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |